Covid19 Clinical Trial
Official title:
Survival and 30-days Hospital Outcome in Hospitalized COVID-19 Patients in Upper Egypt: Multi-center Study
NCT number | NCT04488588 |
Other study ID # | AssiutU17 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | March 15, 2020 |
Est. completion date | July 1, 2020 |
Verified date | July 2020 |
Source | Assiut University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Through history, there have been plenty of pandemics however; the social response to corona
virus disease (COVID-19) is unparalleled. It is assessed that almost four billion individuals
are living in social segregation during this mother of all pandemics.
Initially described in China in December 2019, severe acute respiratory syndrome caused by
corona virus 2 (SARS-CoV-2) has spread all over the world and by 18th July 2020- there was an
emergent figure of 13,824,739 confirmed cases and 591.666 losses reported to the WHO. To
date, Egypt reported slightly over 82,000 confirmed COVID-19 cases with 3858 deaths. The new
pandemic is injuring not only health organizations of several countries but also the
financial prudence universal.
Defining the clinical features and associated outcomes of patients diagnosed with coronavirus
disease (COVID-19) is fundamental to improving our understanding and adequate management of
this illness. Several articles have recently been published, describing the clinical features
and outcomes of retrospective individuals with COVID-19
Status | Completed |
Enrollment | 1064 |
Est. completion date | July 1, 2020 |
Est. primary completion date | May 1, 2020 |
Accepts healthy volunteers | |
Gender | All |
Age group | 36 Years to 63 Years |
Eligibility |
Inclusion Criteria: - This study included 1064 patients consecutively admitted to isolation hospitals in Upper Egypt during the period from 22 March to 23 June 2020 Exclusion Criteria: - only hospitalized confirmed cases of COVID-19 were included. |
Country | Name | City | State |
---|---|---|---|
Egypt | Aliae Mohamed-Hussein | Assiut | |
Egypt | AssiutU | Assiut |
Lead Sponsor | Collaborator |
---|---|
Assiut University |
Egypt,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | number of co-morbidities in hospitalized patients with COVID-19 | Determinants of survival in studied covid-19 patients admitted to hospitals | one month | |
Primary | causes of ICU admission | Determinants of ICU admission in hospitalized patients with COVID-19 | one month |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05047692 -
Safety and Immunogenicity Study of AdCLD-CoV19-1: A COVID-19 Preventive Vaccine in Healthy Volunteers
|
Phase 1 | |
Recruiting |
NCT04395768 -
International ALLIANCE Study of Therapies to Prevent Progression of COVID-19
|
Phase 2 | |
Terminated |
NCT04555096 -
A Trial of GC4419 in Patients With Critical Illness Due to COVID-19
|
Phase 2 | |
Completed |
NCT04506268 -
COVID-19 SAFE Enrollment
|
N/A | |
Completed |
NCT04508777 -
COVID SAFE: COVID-19 Screening Assessment for Exposure
|
||
Completed |
NCT04961541 -
Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04546737 -
Study of Morphological, Spectral and Metabolic Manifestations of Neurological Complications in Covid-19 Patients
|
N/A | |
Terminated |
NCT04581915 -
PHRU CoV01 A Trial of Triazavirin (TZV) for the Treatment of Mild-moderate COVID-19
|
Phase 2/Phase 3 | |
Terminated |
NCT04542993 -
Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy
|
Phase 2 | |
Completed |
NCT04532294 -
Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants
|
Phase 1 | |
Completed |
NCT04494646 -
BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19)
|
Phase 2 | |
Not yet recruiting |
NCT04543006 -
Persistence of Neutralizing Antibodies 6 and 12 Months After a Covid-19
|
N/A | |
Completed |
NCT04537663 -
Prevention Of Respiratory Tract Infection And Covid-19 Through BCG Vaccination In Vulnerable Older Adults
|
Phase 4 | |
Completed |
NCT04387292 -
Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic
|
N/A | |
Not yet recruiting |
NCT04527211 -
Effectiveness and Safety of Ivermectin for the Prevention of Covid-19 Infection in Colombian Health Personnel
|
Phase 3 | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Completed |
NCT04979858 -
Reducing Spread of COVID-19 in a University Community Setting: Role of a Low-Cost Reusable Form-Fitting Fabric Mask
|
N/A | |
Not yet recruiting |
NCT05038449 -
Study to Evaluate the Efficacy and Safety of Colchicine Tablets in Patients With COVID-19
|
N/A | |
Completed |
NCT04610502 -
Efficacy and Safety of Two Hyperimmune Equine Anti Sars-CoV-2 Serum in COVID-19 Patients
|
Phase 2 | |
Active, not recruiting |
NCT06042855 -
ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin)
|
Phase 3 |